hsa-miR-625-5p miREIA

Features

• It is intended for research use only
• The total assay time is less than 2.5 hours
• The kit measures hsa-miR-625-5p isolated from human blood
• Assay format is 96 wells
• Standard is synthetic miRNA-based
• Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Pulmonary diseases

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-625 has been found in various tumors, such as gastric cancer, pancreatic cancer, glioma and melanoma. miR-625 has been shown to be down regulated in gastric cancer. miR-625 is responsible for the regulation of metastasis in gastric tumor cells, and therefore downregulation of miR-625 in increased metastasis. Glioma tissues overexpressing HIF1α exhibited a low expression of miR-625-5p. The knockdown of RHPN1-AS1 inhibited the proliferation, migration and invasion activity of glioma cells via regulating miR-625-5p/REG3A expression. miR-625-5p regulated PKM2 expression on mRNA and protein level in melanoma cells (MC). There was a negative relationship between miR-625-5p and PKM2 expression in the clinical melanoma samples so miR-625-5p/PKM2 plays a role in MC glucose metabolism.

miR-625-5p inhibited cardiac hypertrophy through targeting STAT3 and CaMKII, suggesting miR-625-5p as a novel negative regulator of cardiac hypertrophy. Expression levels of miR-421, miR-1233-3p and miR-625-5p are lower in TOF patients with symptomatic right heart failure and thus may indicate disease progression in these patients. Aortic valve stenosis (AS) is a major cause of morbidity and mortality, with no effective medical therapies. In this connection, downregulation of miR-122-5p, miR-625-5p, miR-30e-5p and upregulation of miR-21-5p and miR-221-3p was confirmed. The identification of a group of tissue miRNA associated with AS may contribute to the development of new therapeutic approaches to AS.

miR 625-5p may function as an inhibitor of asthma airway inflammation in human bronchial epithelial cells (HBECs) by targeting AKT2. Three miRNAs (miR-22-3p, miR 513a-5p, miR-625-5p) were significantly downregulated in the asthma group compared with the control group.